Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovis ABOSTO:GENO -0.10%94 EV-to-FCF is 23.41 as of Aug. 04, 2026, which is 55% below its 10-year median of 51.50. GuruFocus rates OSTO:GENO with a GF Score™ of 94/100 and a GF Value™ of kr26.81 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 348 Biotechnology companies, Genovis AB ranks worse than 60.92% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genovis AB's Enterprise Value is kr1,198.3 Mil.
Genovis AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was kr51.2 Mil. Therefore, Genovis AB's EV-to-FCF for today is 23.41.
The historical rank and industry rank for Genovis AB's EV-to-FCF or its related term are showing as below:
OSTO:GENO'
s EV-to-FCF Range Over the Past 10 Years
Min: -4728.45 Med: 51.5 Max: 774.84
Current: 23.44
During the past 13 years, the highest EV-to-FCF of Genovis AB was 774.84. The lowest was -4728.45. And the median was 51.50.
OSTO:GENO's EV-to-FCF is ranked worse than 60.92% of 348
companies
in the Biotechnology industry
Industry Median: 14.235
vs OSTO:GENO: 23.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genovis AB's share price for today is kr19.10.
Genovis AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genovis AB EV-to-FCF Related Terms
Genovis AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Genovis AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:GENO vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Genovis AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovis AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovis AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Genovis AB's EV-to-FCF falls into.
Genovis AB's current Enterprise Value is kr1,198.3 Mil.
Genovis AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr51.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovis AB (OSTO:GENO) has a EV-to-FCF of 23.41 as of Aug. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genovis AB and its competitors. This is 55% below median its historical median of 51.50. According to the industry distribution chart, Genovis AB ranks #212 out of 348 companies in the Biotechnology industry, placing it in the top 60.9%.
Is Genovis AB's EV-to-FCF too high?
Genovis AB's current EV-to-FCF of 23.41 is 55% below median its 10-year median of 51.50. The Biotechnology industry median EV-to-FCF is 14.24. Genovis AB's value of 23.41 is 64.5% above this industry median. Based on the distribution chart, Genovis AB ranks #212 out of 348 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genovis AB has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovis AB ranks #212 out of 348 companies for EV-to-FCF. This places Genovis AB in the lower half of its industry. The industry median EV-to-FCF is 14.24. Genovis AB's value of 23.41 is 64.5% above this benchmark. While the company's 10-year median is 51.50 vs. the industry median of 14.24, Genovis AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.24, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovis AB's current EV-to-FCF of 23.41 is 64.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genovis AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovis AB's current EV-to-FCF is 23.41, which is 55% below median its own 10-year median of 51.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr26.81, compared to a current price of kr19.10 — trading 28.8% below its estimated fair value. The current EV-to-FCF is 23.41, which is 55% below median its 10-year median of 51.50 and 64.5% above the Biotechnology industry median of 14.24. Genovis AB's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current EV-to-FCF is 23.41 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovis AB (OSTO:GENO) Overvalued in 2026?
Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued.
The current stock price of kr19.10 is trading 28.8% below its estimated GF Value™ of kr26.81.
GuruFocus considers Genovis AB to be Modestly Undervalued.
Key valuation signals for OSTO:GENO:
EV-to-FCF: 23.41 (55% below median its 10-year median of 51.50)
GF Value™: kr26.81 vs. price of kr19.10 (28.8% below fair value)
Industry Position: 64.5% above the Biotechnology median (#212 of 348)
No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
94GF Score
Get the complete analysis for OSTO:GENO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:GENO has been successfully added to your 
